• Anh-Thu Huynh Dang, Vu-Uyen Tran, Thanh-Truong Tran, Hong-Anh Thi Pham, Dinh-Thong Le, Lam Nguyen, Ngoc-Vu Nguyen, Thai-Hoa Thi Nguyen, Chu Van Nguyen, Ha Thu Le, Mai-Lan Thi Nguyen, Vu Thuong Le, Phuc Huu Nguyen, Binh Thanh Vo, Hong-Thuy Thi Dao, Luan Thanh Nguyen, Thien-Chi Van Nguyen, Quynh-Tram Nguyen Bui, Long Hung Nguyen, Nguyen Huu Nguyen, Quynh-Tho Thi Nguyen, Truong Xuan Le, Thanh-Thuy Thi Do, Kiet Truong Dinh, Han Ngoc Do, Minh-Duy Phan, Hoai-Nghia Nguyen, Le Son Tran, and Hoa Giang.
• University of Medicine and Pharmacy at Ho Chi Minh city, Ho Chi Minh city, Vietnam.
• Sci Rep. 2020 Feb 17; 10 (1): 2707.

AbstractComprehensive profiling of actionable mutations in non-small cell lung cancer (NSCLC) is vital to guide targeted therapy, thereby improving the survival rate of patients. Despite the high incidence and mortality rate of NSCLC in Vietnam, the actionable mutation profiles of Vietnamese patients have not been thoroughly examined. Here, we employed massively parallel sequencing to identify alterations in major driver genes (EGFR, KRAS, NRAS, BRAF, ALK and ROS1) in 350 Vietnamese NSCLC patients. We showed that the Vietnamese NSCLC patients exhibited mutations most frequently in EGFR (35.4%) and KRAS (22.6%), followed by ALK (6.6%), ROS1 (3.1%), BRAF (2.3%) and NRAS (0.6%). Interestingly, the cohort of Vietnamese patients with advanced adenocarcinoma had higher prevalence of EGFR mutations than the Caucasian MSK-IMPACT cohort. Compared to the East Asian cohort, it had lower EGFR but higher KRAS mutation prevalence. We found that KRAS mutations were more commonly detected in male patients while EGFR mutations was more frequently found in female. Moreover, younger patients (<61 years) had higher genetic rearrangements in ALK or ROS1. In conclusions, our study revealed mutation profiles of 6 driver genes in the largest cohort of NSCLC patients in Vietnam to date, highlighting significant differences in mutation prevalence to other cohorts.

50 keywords...

hide…